Maria Hägg Olofsson

TL;DR: Treatment with b-AP15 inhibited tumor progression in four different in vivo solid tumor models and inhibited organ infiltration in an acute myeloid leukemia model, showing that the deubiquitinating activity of the 19S regulatory particle is a new anticancer drug target.

TL;DR: The small molecule VLX600 is identified as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues and displays tumour growth inhibition in vivo, suggesting that tumours in metabolically compromised microenvironments have a limited ability to respond to decreased mitochondrial function.

TL;DR: Induction of necrotic cell death may explain the clinical efficacy of anthracycline-based therapy for breast carcinomas with defective apoptosis pathways and is suggested to be useful biomarkers for clinical trials.

TL;DR: Targeting of the TXN pathway alone and selective inhibition of the cytosolic selenocysteine-containing enzyme TXN reductase 1 (TXNRD1) are evaluated to display the therapeutic anticancer potential of irreversibly targeting cytosol TXNRD 1 using small molecules and present potent and selective TXNRd1 inhibitors.

TL;DR: It is reported that the FDA-approved anthelmintic drug nitazoxanide could be a potential candidate for advancement into cancer clinical trials and it is shown that all five compounds inhibit mitochondrial respiration, suggesting that cancer cells in low glucose concentrations depend on oxidative phosphorylation rather than solely glycolysis.